Changeflow GovPing Pharma & Drug Safety Quinoline Butenamide Maleate Salts for EGFR Can...
Routine Notice Added Draft

Quinoline Butenamide Maleate Salts for EGFR Cancer Treatment

Favicon for changeflow.com ChangeBridge: Patent Apps - Organic Chemistry (C07D)
Published
Detected
Email

Summary

The USPTO published patent application US20260092046A1 covering maleate salt forms of a quinoline-based butenamide compound designed to target epidermal growth factor receptor (EGFR) family kinases for cancer treatment. Invented by Quinhong Lu and colleagues, the application discloses crystalline forms, preparation methods, and pharmaceutical compositions. The patent application was filed on May 5, 2025, and published on April 2, 2026.

What changed

The USPTO published patent application US20260092046A1 for maleate salt forms of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, a quinoline compound targeting EGFR family kinases for cancer therapy. The application (No. 19199238) includes seven inventors and covers crystalline forms, methods of preparation, and associated pharmaceutical compositions.\n\nPharmaceutical companies and drug manufacturers developing kinase inhibitors or EGFR-targeted cancer therapeutics should review this patent landscape to assess potential freedom-to-operate considerations. This is a published patent application, not a granted patent or regulatory requirement, so no immediate compliance action is required.

Archived snapshot

Apr 2, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

MALEATE SALTS OF (E)-N-{4-[3-CHLORO-4-(2-PYRIDINYLMETHOXY)ANILINO]-3-CYANO-7-ETHOXY-6-QUINOLINYL}-4-(DIMETHYLAMINO)-2-BUTENAMIDE AND CRYSTALLINE FORMS THEREOF

Application US20260092046A1 Kind: A1 Apr 02, 2026

Inventors

Quinhong Lu, Mannching Sherry Ku, Warren Chew, Gloria Cheal, Anthony F. Hadfield, Mahmoud Mirmehrabi

Abstract

The present invention relates to maleate salt forms of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide, methods of preparing crystalline maleate salt forms, the associated compounds, and pharmaceutical compositions containing the same. The maleate salts are useful in treating cancers, particularly those affected by kinases of the epidermal growth factor receptor family.

CPC Classifications

C07D 401/12 A61K 31/4709 C07C 51/412 C07C 57/145

Filing Date

2025-05-05

Application No.

19199238

View original document →

Get daily alerts for ChangeBridge: Patent Apps - Organic Chemistry (C07D)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The plain-English summary, classification, and "what to do next" steps are AI-generated from the original text. Cite the source document, not the AI analysis.

Last updated

Classification

Agency
USPTO
Published
April 2nd, 2026
Instrument
Notice
Legal weight
Non-binding
Stage
Draft
Change scope
Minor
Document ID
US20260092046A1

Who this affects

Applies to
Pharmaceutical companies Drug manufacturers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Pharmaceutical Research Drug Development
Geographic scope
United States US

Taxonomy

Primary area
Pharmaceuticals
Operational domain
Legal
Topics
Healthcare Intellectual Property

Get alerts for this source

We'll email you when ChangeBridge: Patent Apps - Organic Chemistry (C07D) publishes new changes.

Optional. Personalizes your daily digest.

Free. Unsubscribe anytime.